Skip to main content
Ghana Medical Journal logoLink to Ghana Medical Journal
. 2020 Dec;54(4 Suppl):52–61. doi: 10.4314/gmj.v54i4s.9

COVID-19 autopsy reports from the Ga-East Municipal and the 37 Military Hospitals in Accra, Ghana

Seth Attoh 1, Roxana P Segborwotso 3, Samuel K Akoriyea 4, Gina Teddy 5, Lawrence Edusei 6, Frederick Hobenu 1, Kwasi Agyemang-Bediako 1, Alfred Toppar 2, Raymond D Fatchu 1, Patrick K Akakpo 7
PMCID: PMC8087362  PMID: 33976442

Summary

Introduction

Since the declaration of COVID-19 by the World Health Organisation (WHO) as a global pandemic on 11th March 2020, the number of deaths continue to increase worldwide. Reports on its pathologic manifestations have been published with very few from the Sub-Saharan African region. This article reports autopsies on COVID-19 patients from the Ga-East and the 37 Military Hospitals to provide pathological evidence for better understanding of COVID-19 in Ghana.

Methods

Under conditions required for carrying out autopsies on bodies infected with category three infectious agents, with few modifications, complete autopsies were performed on twenty patients with ante-mortem and/or postmortem RT -PCR confirmed positive COVID-19 results, between April and June, 2020.

Results

There were equal proportion of males and females. Thirteen (65%) of the patients were 55years or older with the same percentage (65%) having Type II diabetes and/or hypertension. The most significant pathological feature found at autopsy was diffuse alveolar damage. Seventy per cent (14/20) had associated thromboemboli in the lungs, kidneys and the heart. Forty per cent (6/15) of the patients that had negative results for COVID-19 by the nasopharyngeal swab test before death had positive results during postmortem using bronchopulmonary specimen. At autopsy all patients were identified to have pre-existing medical conditions.

Conclusion

Diffuse alveolar damage was a key pathological feature of deaths caused by COVID-19 in all cases studied with hypertension and diabetes mellitus being major risk factors. Individuals without co-morbidities were less likely to die or suffer severe disease from SARS-CoV-2

Funding

None declared

Keywords: COVID-19, Ghana, autopsy, thromboemboli, Diffuse Alveolar Damage

Introduction

Coronavirus disease 2019 (COVID-19) was declared by the World Health Organization (WHO) on the 11th of March 2020 as a global pandemic.1 COVID-19 is caused by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARSCoV-2) an RNA virus that belongs to the Coronavirus family.

Other members of this family have been responsible for previous deadly outbreaks of infection.2 SARS-CoV-2, the virus responsible for the current outbreak causes severe disease in people with other co-morbid conditions such as diabetes mellitus and hypertension and also in older people. Majority of infected patients have however been reported to be asymptomatic.3

Though the number of deaths from COVID-19 have continued to increase worldwide, only a handful of reports on the pathologic manifestations of COVID-19 have been published as at April 2020.2 In Ghana, the total number of confirmed cases as of 14 August 2020 was 42,532 with 231 deaths, yet a report of pathological manifestations of COVID-19 is yet to be published from Ghana.4

In elderly people and patients with co-morbidities, the more severe clinical presentation and course of COVID-19 infection is characterized by the clinical picture of Acute Respiratory Distress Syndrome (ARDS) with its pathological correlate of Diffuse Alveolar Damage (DAD) and Hyaline Membrane (HM) formation in the alveoli.2,5 This pathological feature has been consistently reported in pathological descriptions of COVID-19 and appears to be the most significant cause of mortality and morbidity.6 Less commonly, pulmonary edema, fibrinous exudates, focal reactive type II pneumocyte hyperplasia and bronchopneumonia with scattered multinucleated giant cells have also been reported.7,8,9 Together, these pathological findings have guided management protocols around the world.

Pathological changes in other organs have not gained as much attention as those in the lungs probably because of the more overt clinical course of the lung pathology (ARDS). Pathological findings in the gastrointestinal tract have been reported to include segmental dilatation and stenosis of the small intestine.7 Other gastrointestinal findings include degeneration, necrosis and shedding of the gastrointestinal mucosa, occasional lymphocytic infiltration in the oesophageal squamous epithelium, and abundant infiltrating plasma cells and lymphocytes with interstitial oedema in the lamina propria of the stomach, duodenum and rectum.7 In the urinary system, there have been reports of non-specific severe acute tubular injury with endothelial injury pattern and evidence of direct parenchymal tubular epithelial and podocyte viral infection.12 Again, the presence of pre-existing cardiovascular disease, appears to predispose patients to the development of cardiovascular complications, which are in turn associated with higher mortality rates.13 As an underlying pathological mechanism, endotheliitis has been highlighted as a basis for the vascular manifestations of COVID-19 infection in all affected organs.14

Our objective was to present the histopathological findings following autopsy of 20 COVID-19 patients at the Ga-East Municipal and the 37 Military Hospitals in Accra, Ghana. We provide pathological evidence for better understanding and improved management of COVID-19 patients in Ghana.

Methods

Ethical clearance with reference number 37MH-IRB IPN/MAST/402/2020 was received from the Institutional Review Board of the 37 Military Hospital. With few modifications to conditions required for carrying out autopsies on bodies infected with category three infectious agents, complete autopsies were performed between April 2020 and June, 2020, on twenty patients with either an RT-PCR confirmed positive COVID-19 results, or presumed cases but with a positive RT-PCR at autopsy. Post-mortems were performed (on average 2 days after death) following WHO guidelines for Infection Prevention and Control for the safe management of a dead body in the context of COVID-19.16 The structural design of suites used lacked negative pressure systems with filters. As a result, extractors were fitted to provide unidirectional airflow away from the Anatomical Pathology Team (APT) into the atmosphere as an appropriate technology. Also, each member of the APT was carefully selected to exclude those with chronic conditions such as diabetes mellitus, cardiovascular and respiratory diseases. The clinical data of each patient was reviewed prior to the autopsy. The autopsy examination included complete gross external and internal examinations in addition to histopathological examination of all major wellpreserved organs (lungs, heart, liver, kidney, brain).

Results

Twenty patients of age between 20 years and 79 years who tested positive for COVID-19 prior to or after death are presented. There was equal proportion of males and females. Thirteen (65%) of our patients were 55years or older with the same percentage (65%) having Type II Diabetes Mellitus (DM) and/or hypertension (HPT). Most of these patients presented with respiratory symptoms of varying severity with decreased saturation on intranasal oxygen (INO2) in association with other constitutional symptoms such as fever, headache, malaise, generalized weakness and collapse. There was an out of the ordinary patient (Case17) who had an initial presentation of tonic clonic seizures with epistaxis, haematuria and bleeding from the vagina with decreased platelets (46 × 109/L). She later developed respiratory distress. Almost all the patients had co-morbid conditions. Details of patients' clinical presentation are summarized in Table 1

Table 1.

Clinical summary of 20 cases with ARDS and positive RT-PCR at autopsy

ID Sex Age
(yr)
Presentation Clinical Signs Co-morbidities Results of Imaging Results of Lab
investigations
Clinical diagnosis and
Treatment
Significant autopsy findings Cause of Death
1. M 41 Cough, difficulty
in breathing,
headache for five
days, positive
travel history
Obese and Cyanosed DM, obesity Patchy opacification on
chest X-ray
Elevated blood glucose
COVID-19 positive
HPT/DKA
Received insulin / antibiotics,
INO2
Died four days after admission
Severe congestion and oedema of
lungs with foci of consolidation.
Thrombus in coronary vessel
COVID-19 pneumonia
with severe DM
2. M 55 Fever, difficulty
in breathing, sore
throat, chest pain
for a week
Fever, reduced oxygen saturation HPT/DM Ground-glass appearance
on chest X-ray
Elevated blood glucose
and
COVID-19 positive
HPT/DM
Received Azithromycin, Hydroxychloroquine,
Metformin and
Glibenclamide.
Died three days after admission
Central cyanosis, Haemorrhage on
pleural surfaces, massive right PE
Acute PE from COVID-19
pneumonia in a
HPT/DM.
3. F 39 Generalized
weakness, difficulty
in breathing
for two weeks.
Respiratory distress, bronchial
breath sounds with bilateral
basal crepitations
HIV Patchy opacification on
chest X-ray
HIV I and II Positive
COVID-19 Positive.
Bilateral pneumonia, COVID-19.
Started on Ceftriaxone, Azithromycin,
Prednisolone, Dalteparin
and Co-trimoxazole.
Died four days after admission
Advanced Autolysis of internal organs.
Congestion and oedema Interstitial
fibrosis, eosinophilic masses
in alveoli
COVID-19 pneumonia in
a patient with HIV
4. F 33 Severe headache,
dizziness, palpitations,
blocked
nostrils, difficulty
in breathing, fever,
vomiting for a
month
High BP Late Pregnancy Live Fetus on USG, diffuse
bilateral hilar opacity
on X-ray
D-dimers elevated
COVID-19 positive
PE, COVID-19 pneumonia. Pre-eclampsia.
Received Heparin,
Amoxicillin clavulanate, Azithromycin,
MgSO4, Methyl dopa,
Dexamethasone, INO2
Died after four days
Congested Lungs, LVH, subcapsular
liver hemorrhage
COVID-19 pneumonia in
a patient with pre-eclampsia
5. F 66 Right-sided weakness,
aphasia, difficulty
in breathing,
headache for
four days
Respiratory distress, dull
percussion note, bronchial
breath sounds
HPT Head CT showed cystic
dilatation of left frontal
lobe, small vessel ischaemia
COVID-19 positive PE, COVID-19. Dalteparin,
Azithromycin, Zinc and Vitamin
C.
Died same day
Obese, petechial hemorrhage on
pleural surfaces, congestion and
edema of lungs, PE
PE, COVID- 19 in a hypertensive
with small vessel
ischemia
6. M 60 Cough, dyspnea,
palpitations for a
week
Unconscious, diaphoretic,
reduced air entry bilaterally
HPT/DM Nil Low platelet count,
Elevated D-dimer
No COVID-19 test
done
Bilateral Pneumonia, MI
On Metformin and Amlodipine
Died same day
Cyanosed, petechial hemorrhages
on pleural surfaces, severe congestion,
moderate edema, Bilateral
Massive PE, CLVH
Bilateral Massive PE
from COVID-19 pneumonia
in a known HPT/DM
7. F 79 General malaise,
difficulty in
breathing, left leg
pain for two
weeks.
Febrile, respiratory distress,
reduced air entry,
bronchial breath sounds
Chronic kidney disease Patchy opacification on
chest X-ray
Anemia, Elevated
potassium, creatinine,
and urea. Low
EGFR
COVID-19 positive
Pneumonia, chronic kidney disease
Given Azithromycin, Dalteparin,
Hydroxychloroquine, Zinc and
Vitamin C
Died same day
Cyanosis, congested, firm and
mildly edematous lungs, shrunken
kidneys, coarsely granular sub-capsular
surfaces, poor cortico-medullary
differentiation. Microthrombi
in pulmonary arteries
COVID-19 bronchopneumonia
in a patient with
chronic kidney disease
8. M 70 Anorexia, lethargy
for three days
Pale, febrile, transmitted
sounds coarse crepitations.
HPT/DM/
Bronchitis
Patchy opacification on
chest X-ray
Elevated blood glucose,
COVID-19
positive
COVID-19, HPT/DM.
Given Insulin, Azithromycin,
Ceftriazone, Dalteparin
Died after two days on admission
Cyanosis
Bilateral pleural effusion, Bilateral
patchy consolidation, LVH
COVID-19 bronchopneumonia
in a known
HPT/DM with Bronchitis
9. F 70 Difficulty in
breathing, weakness,
lethargy for
two weeks
Respiratory distress, Reduced
air entry bilaterally,
morbid obesity
HPT/DM, obesity Ground glass appearance
on chest X-ray
Elevated blood glucose,
COVID-19
positive
HPT/DM, COVID-19
Azithromycin, Ceftriazone, Dalteparin,
Hydrocortisone
Died same day
Morbidly obese, central cyanosis,
Edematous and congested lungs,
Bilateral hypostatic consolidation,
Bilateral PE.
Bilateral PE, COVID-19
pneumonia in a known
HPT/DM
10. F 60 Difficulty in
breathing, cough
for three weeks.
Obese, respiratory
distress
HPT/DM, obesity Chest CT scan showed
consolidation with air
bronchograms
High D-dimer, elevated
WBC, Deranged
liver enzymes
COVID-19 negative
PE, CCF, COVID-19
Given Azithromycin, Ceftriazone,
Dalteparin, Hydrocortisone, Insulin
and Amlodipine
Died after 10 days of admission
Petechial hemorrhages on pleural
surfaces heavy lungs with severe
congestion and edema. PE, CLVH
Acute PE due to COVID-19
Pneumonia in a
HPT/DM
11. M 55 Cough, dyspnea,
fever, general
weakness, headache
for seven
days. Positive
travel history
Respiratory distress,
febrile, bronchial breath
sounds,
basal
crepitations
HPT/DM X-ray and CT scan
showed ground glass appearance
Elevated blood glucose,
Low Hb, High
WBC
No COVID-19 test
done
Bilateral COVID-19 pneumonia,
HPT/DM
Given Azithromycin, Ceftriazone,
Dalteparin, Hydrocortisone, Insulin
and Amlodipine
Died after two days of admission
Petechial hemorrhages on lung surface.
Heavy lungs with severe congestion
and moderate edema. Bilateral
massive PE.
PE, COVID-19 pneumonia
with HPT/DM
12. F 37 Difficulty in
breathing, bilateral
pedal swelling,
abdominal
distention for two
weeks
Cyanosed, mild jaundice,
bi-pedal pitting edema, fever,
diastolic murmur
Atrial myxoma
Post-thyroidectomy,
CCF
Echocardiography-Atrial
myxoma-
COVID-19 negative CCF secondary to atrial myxoma,
bilateral pneumonia. Started on
Furosemide, azithromycin, Ceftriaxone,
Fluconazole, Aldactone,
Thyroxine
Died after three days of admission
Severely congested lungs with bilateral
hypostatic consolidation, atrial
myxoma with thrombus, CCF, MI
COVID-19 pneumonia,
CCF due to left atrial
myxoma
13. M 62 General malaise,
easy fatigability,
difficulty in
breathing for two
weeks
Respiratory distress, Reduced
air entry bilaterally
with crepitations
HPT CT scan of the chest
showed extensive peripheral
and basal
ground glass opacities
Elevated blood
sugar, COVID-19
negative
Bilateral pneumonia, COVID-19,
HPT/DM
Given Azithromycin, Ceftriazone,
Dalteparin, Hydrocortisone, Insulin
and Amlodipine
Died six days after admission
Both lungs are heavy with severe
congestion and moderate edema.
Bilateral hypostatic consolidation
COVID-19
bronchopneumonia in a
HPT/DM
14. M 62 Fever, difficulty
in breathing,
cough for five
days
Fever, reduced oxygen saturation,
reduced air entry
with bronchial breath
sounds
HPT Nil COVID-19 test not
done
Acute left ventricular failure due
to HPT, COVID-19, PE
Given furosemide, Enoxaparin
Died in ambulance
Congested, edematous lungs, dilated
left ventricle with LVH, MI
Microthrombi in pulmonary arteries
COVID-19 pneumonia.
Acute left ventricular failure
due to MI in a known
hypertensive
15. M 61 Generalized
weakness, difficulty
in breathing,
fever, dry cough
for six hours
Respiratory distress, fever,
basal crepitations bilaterally,
reduced SPO2
HPT/DM Nil Elevated blood sugar
No COVID-19 test
done
Bilateral Pneumonia, COVID-19.
Started on Ceftriaxone, Azithromycin,
Dalteparin, Co-trimoxazole.
Died following day
Heavy congested lungs, CLVH COVID-19 pneumonia in
a known HPT/DM
16. M 57 Found dead in
room
Nil HPT Nil No COVID-19 test
done
Unknown
Brought-in-dead
Right lower lobe consolidation,
CLVH, Microthrombi in pulmonary
vessels
COVID-19 pneumonia
with secondary bacterial
infection in a known hypertensive
17. F 20 Fever, vomiting,
diarrhea for three
days, sudden collapse
Respiratory distress, unrecordable
BP, high pulse
rate, tonic clonic seizures,
haematuria, epistaxis, vaginal
bleeding
None Nil Elevated blood
sugar, low platelet,
Retro negative,
pregnancy test negative
COVID-19 Positive
Shock, DIC, Gastroenteritis
Started on Dexamethazone,
Clindamycin, Insulin, Phenytoin,
Meropenem, Fresh frozen Plasma
Died same day
Cyanosed, Severe systemic congestion
Congested and edematous lungs
Microthrombi in pulmonary vessels
COVID-19 pneumonia in
a newly diagnosed diabetic
18. F 31 Increasing difficulty
in breathing,
cough for a week
Fever, contractions, 35 weeks Pregnant,
one previous C/S
Patchy opacification on
chest X-ray
COVID-19 Negative Atypical Pneumonia, COVID-19,
Emergency C/S after 2 days,
Azithromycin, Cefuroxime,
Dalteparin, Zinc, Vitamin C, Dexamethazone
Died 6 days after C/S
Congested and heavy lungs COVID-19 pneumonia in
pregnancy
19. F 28 Worsening breathlessness
for four
days
Fever, reduced air entry bilaterally,
low SPO2
None Ground-glass appearance
on chest X-ray
Thrombocytopaenia
COVID-19 Negative
COVID-19 pneumonia to rule out
PE. Given Dalteparin, Ceftriaxone,
Azithromycin and Dexamethasone
Died same day
Systemic Congestion, Firm congested
Lungs, Left Adrenal Adenoma,
Microthrombi in lungs and
kidneys
COVID-19 pneumonia
with adrenal adenoma
20. M 61 Sore throat, difficulty
in breathing,
general body
weakness, diarrhea,
cough for
four days, right
leg ulcer
Obese, pale, fever,
swollen, warm and ulcerating
right leg
HPT/DM Patchy opacification on
chest X-ray
COVID-19 negative Diabetes Mellitus with Right leg
ulcer, MI, PE. Given
Ceftriazone, Clindamycin
Dalteparin, Azithromycin, Insulin,
Amlodipine, Acetyl salicylic acid
Died following day
Congested, firm, heavy lungs, fibrinous
exudates on lung surfaces,
PE, CLVH
Massive PE with COVID-19
pneumonia in a known
HPT/DM

Grossly, the significant autopsy findings were respiratory in nature. Findings included, pulmonary thromboemboli (PE) involving both the larger and smaller pulmonary artery branches of the lungs in some patients (details provided in Table 1).

This was associated with petechial haemorrhage on the surfaces of the lungs and areas of hemorrhagic infarction. In general, however there were frothy secretions in the larynx, trachea and bronchi, and the lungs were usually heavy, firm, severely congested with moderate to severe pulmonary edema and various degrees of consolidation. The hearts of hypertensive patients were enlarged and showed concentric left ventricular hypertrophy (CLVH) in keeping with hypertensive heart disease. There was an isolated case of a patient with an atrial myxoma (Case 12) who had a friable soft gelatinous mass measuring 45x30mm attached to the anterior wall of the left atrium, 12mm above the annulus of the anterior leaflet of the mitral valve. This was consistent with the antemortem clinical diagnosis. Again, this patient had isolated dilatation of all the chambers of the heart except the left ventricular chamber. In this patient and another (Case 14), there were areas of scaring in the left ventricle suggestive of previous myocardial infarction.

The liver was heavy and showed fatty change in most patients. In general, however the liver was moderate to severely congested in all patients though no other significant pathology was found except in a pregnant patient who had a subcapsular bleed (Case 4).

The kidneys showed no significant changes in most patients except one in whom the kidneys were small in size and showed coarsely granular subcapsular surface (Case 7). There was a patient with an adrenal adenoma (Case 19) and another with a cystic mass in the brain (Case 5) but no other patient had any significant findings in the brain. There were no other significant findings in any other organs.

The most significant findings on histopathological examination were respiratory, in agreement with the gross findings. Sections from patients' lungs showed severe edema within the lungs (Figure 1A, B, C, D), sometimes seen as eosinophilic blobs (Figure 1F& 2 F), with mild to severe inflammatory cell exudates, made up of neutrophils, lymphocytes, macrophages, giant cells with a predominance of different cells in different patients (Figure 1A&E, 2B, 2D). There are fibroblasts in areas (Figure 2A). In some patients, lymphocytes dominated while in others, neutrophils predominated (Case 8) (Figure 1B). There were scattered macrophages including multinucleated giant cells (Cases 1,2,9 and 10) (Figure 2D). These inflammatory cells were in the alveolar spaces and the interstitium. There were prominent atypical pneumocytes with prominent type II pneumocyte proliferation in most patients (Figure 2. B, C, D, E). These pneumocytes were large and showed enlarged nuclei and granular amphophilic cytoplasm (Figure 2 B). The most significant finding was DAD and widespread HM seen lining the alveoli in all cases (Figure 1A, C, D). This was coupled with microthrombi in medium to small sized vessels in some patients (Figure 3F). Fibrin thrombi mostly located in the subpleural region were also noted. There were also foci of fibrosis in the lungs (Case 19). The significant findings within the lungs are shown in Figures 1 and 2 and 3B.

Figure 1.

Figure 1

Haematoxylin & Eosin staining of lung tissue samples in patients with COVID-19(37 Military Hospital, Accra, Ghana, April 2020 to June 2020) X100. A. Diffuse alveolar damage (DAD) with presence of hyaline membrane (HM) (yellow arrow), alveolar oedema (blue arrow), congestion of pulmonary capillary (green arrow), focal accumulation of neutrophils (black arrow) and microthrombi (red arrows). B. DAD with HM (black arrow), oedema (red arrow), congestion (blue arrow), intra-alveolar accumulation of neutrophils (green arrow) and eosinophilic blobs(yellow arrow). C. DAD with HM (red arrow), oedema (black arrows), congestion (green arrow) with peri-vascular lymphocytic infiltrates (yellow arrow). D. DAD with HM formation in a moderately preserved body (black arrows), oedema (green arrow) and interstitial fibrosis with lymphocytic infiltrate (blue arrow). E. Alveolar exudate consisting of neutrophils, red blood cells, macrophages (black arrows) and poorly formed HM (red arrows). F. HM appearing as eosinophilic blobs in a poorly preserved body (red arrows)

Figure 2.

Figure 2

Hematoxylin & Eosin staining of lung tissue samples of patients with COVID-19 (37 Military Hospital, Accra, Ghana, April 2020 to June 2020) X400. A. Severe congestion with intra-alveolar proliferation of fibroblasts (black arrows). B. Neutrophilic accumulation (green arrow), Type 2 pneumocyte hyperplasia (red arrow) and HM presence (black arrow). C. Macrophage (yellow arrow), congestion (green arrow), Type 2 pneumocytes (red arrow), neutrophils (black arrow) and HM (blue arrow). D. Intra-alveolar macrophages (green arrow) including multinucleated giant cells (blue arrows). E. DAD with HM formation (black arrow), Type 2 pneumocyte hyperplasia (red arrow), congestion with peri-vascular lymphocytic infiltrates (green arrow). F. Formation of eosinophilic blob in an alveolus

Figure 3.

Figure 3

Haematology & Eosin staining of various organs and tissues with microthrombi in patients with COVID-19 (37 Military Hospital, Accra, Ghana, April 2020 to June 2020) X100. A. Section of the heart muscle (red arrow) showing a thrombus (green arrow) in a coronary artery (black arrow). B. Vasa vasora (arrows) of a branch of pulmonary artery showing thrombi (red arrows). C. Thrombi(arrows) in a vessel of an atrial myxoma with presence of vegetations (red arrows). D. Thrombus in an arteriole of the kidney(arrow). E. Thrombus on the surface of the heart(arrows). F. Thrombus in a pulmonary arteriole(arrow)

Other organs such as the heart in Case 1 showed thickened myocytes and a thrombus within a coronary vessel but without evidence of an infarct (Figure 3A). There was also microscopic evidence of atherosclerotic narrowing with and without infarction of the myocardium in some patients. A thrombosed vessel within a myxoma (Figure 3C) in addition to a thrombus on the surface of the endocardium (Figure 3E) was seen in Case 12. Microthrombi were also noted in some glomeruli (Figure 3D), as observed in Case 10. In one patient there was widespread microthrombi in different organs, even within vasa vasora of vessels (Case 9) (Figure 3 B).

Significant histological findings in the liver included severe macrovesicular steatosis of the hepatocytes with moderate mononuclear inflammatory cell infiltrates in the portal tracts.

Discussion

Our experience revealed that prior to autopsy, most bodies were sub-optimally preserved. This was due to delays in removing bodies to the autopsy suite because there were protocols in place that needed to be followed in order to avoid spread of the infection. The very warm, humid environmental conditions at that time of the year also contributed to the rapid deterioration of some of the bodies. In addition, all the bodies needed to be sprayed with chlorine as a disinfection practice stipulated by the accepted protocols for managing deaths from COVID-19. In order to obtain the best results from histopathological examination however, bodies and thus internal organs needed to be well preserved. It therefore took between 9 and18 hours before the bodies were put into the fridge. Then again, the autopsies had to be done in a timely manner while observing laid down autopsy protocols for carrying out autopsies on category-3 and 4 infectious organisms such as SARS-CoV-2. To achieve this, bodies of deceased patients had to be removed in a timely fashion to the COVID-19 theatre in the autopsy suite for examination.

In relation to category 3 and 4 infectious organisms, there is currently no working, completely well-equipped autopsy suite in Ghana for carrying out such autopsies. The structural design of our autopsy suites lacks the negative pressure systems with filters recommended by the WHO.16 In this regard, appropriate technology, as described in the methodology was employed in the autopsy suites and all autopsies carried out with improvised equipment in improvised theatres. A critical look at autopsy practice and infrastructure in Ghana is recommended to improve practice, research and evidence.

There was equal proportion of males and females in the cases presented. Thirteen (65%) of the cases were 55 years or older, a finding that is consistent with worldwide reports on COVID-19 deaths which consistently report deaths in older people who also tend to live with comorbidities.2,5 These reports, however, also show the vulnerability of younger people with comorbidities to the infection and subsequent death from COVID-19. Our findings are consistent with these reports with some deaths occurring in patients younger than 40 years in our series.2,5 These individuals had comorbidities. It is evident that all patients had other underlying health conditions with most being hypertensive and or diabetic (65%). This is in line with previous reports that the clinical presentation of COVID-19 infections varies from mild to severe disease with severe disease reportedly present in patients with co-morbidities.6 Other comorbid conditions in our series included complicated atherosclerosis (CAD), atrial myxoma, adrenal tumour, HIV and ‘pregnancy state’. Though there are other co-morbid conditions in Ghanaians such as sickle cell disease, pulmonary tuberculosis, there is currently no local report of pathological findings in such patients who die of COVID-19.

Forty percent (6/15) of our cases that had the nasopharyngeal swab test before death had negative results for COVID-19 but had positive results at post-mortem. This is consistent with earlier reports that broncho-alveolar lavage specimen is more sensitive than the nasopharyngeal swab.15,17 It is therefore recommended that postmortems should be encouraged in presumed COVID-19 patients who die despite testing negative for SARS-CoV-2.

Severe COVID-19 disease is characterized histopathologically by DAD with deposition of HMs that result in diffusion-perfusion mismatch in the lung characterized clinically by Acute Respiratory Distress Syndrome (ARDS) in which there is respiratory hypoxemia that is refractory to oxygen.7,8,9 In the acute stage of DAD there is HM formation.6 All our cases had HMs deposited in the lungs. Again, there was significant pulmonary edema in all the patients. Previous reports state that interstitial widening by edema and fibroblast proliferation are prominent in the organizing stage of DAD/ARDS.5

Additional pathological features that have been reported in the lung include reactive hyperplasia limited to some type-II pneumocytes and patchy inflammatory changes with scattered multinucleated giant cells.8,9 These were features that were present to varying degrees in some patients. The presence and significance of multinucleated giant cells remain unexplained. In some patients, a clinical diagnosis of bronchopneumonia was made following initial clinical findings suggestive of such.5 These included findings on clinical examination (auscultation) and imaging.

A number of our patients had pulmonary thromboemboli within both the major pulmonary artery branches and smaller pulmonary artery branches (70%). The role of stasis, endotheliitis and other factors that affect susceptibility to thrombosis in relation to COVID-19 infection needs to be properly studied in order to understand the causal role played by COVID-19 infection. However, the prominent role of endotheliitis in COVID-19 infection related thrombosis has been reported with suggestions that infection with SARS-CoV-2 results in endotheliitis in several organs from their involvement by the virus and as part of the host inflammatory response. It is believed that a strategy that targets endotheliitis in susceptible patients is likely to improve survival in such patients.14,17 Considering most of our patients had DM and or HPT in addition to being obese and also being bed ridden because of sickness, it is likely that COVID-19 infection has a contributory role in predisposing these patients to thrombosis.

Pathological features in other organs including the liver and heart were less significant with mostly a confirmation of pre-existing hypertensive heart disease or fatty liver as in other reports.6,17 The finding of fatty liver in some patients may be related to their preexisting obesity as part of a metabolic syndrome and not to the COVID-19 infection. Again, CLVH is an end result of systemic hypertension. In our experience, the causal role of COVID-19 infection in the context of pre-existing chronic disease or infection is difficult to unravel.

Conclusion

The majority of the patients autopsied had pre-existing medical conditions with the commonest being HPT and DM. The most significant pathological feature of the patients who died of COVID-19 was DAD. A management approach that recognizes early onset ARDS/DAD and aggressively treats or prevents further damage to the lung may improve the survival of patients.

Acknowledgement

Sincere thanks to the prosectors at the Ga-East Municipal Hospital and the 37 Military Hospital for their assistance during the autopsies. Again, we are grateful to the biomedical scientists at the JM Wadhwani Department of Anatomical Pathology, 37 Military Hospital for preparing the histopathology slides.

References

  • 1.WHO, author. WHO January update [Internet] 2020. Available from: https://www.who.int/csr/don/12january-2020-novel-coronavirus-china/en/
  • 2.Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S. COVID-19 Autopsies, Oklahoma, USA. Am J Clin Pathol. 2020:725–733. doi: 10.1093/ajcp/aqaa062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Wu Z, McGoogan JM. Asymptomatic and Pre-Symptomatic COVID-19 in China. Infect Dis Poverty. 2020;9(1):10–11. doi: 10.1186/s40249-020-00679-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.COVID-19 Updates / Ghana. Ghana Health Service; 2020. https://ghana-healthservice.org/covid19/archive.php. Retrieved 14th August 2020. [Google Scholar]
  • 5.Tian S, Hu W, Niu L, Liu H. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients with Lung Cancer. J Thorac Oncol. 2020;15(January):700–704. doi: 10.1016/j.jtho.2020.02.010. Elsevier. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Temgoua MN, Endomba FT, Nkeck JR, Kenfack GU, Tochie JN, Essouma M. Coronavirus Disease 2019 (COVID-19) as a Multi-Systemic Disease and its Impact in Low- and Middle-Income Countries (LMICs) SN Compr Clin Med. 2020;2019 doi: 10.1007/s42399-020-00417-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Tian Y, Rong L, Nian W, He Y. Review article: Gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020;51(9):843–851. doi: 10.1111/apt.15731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Huang C, Wang Y, Li XL, Ren L, Zhao J, Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(February):497–506. doi: 10.1016/S0140-6736(20)30183-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Tang D, Comish P, Kang R. The hallmarks of COVID-19 disease. PLoS Pathog [Internet] 2020;16(5):1–24. doi: 10.1371/journal.ppat.1008536. Available from: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Wai-Fu N, Ka-Fai T, William W, Tak-Keung, Lee KC. The comparative pathology of severe acute respiratory syndrome and avian influenza A subtype H5N1 - A review. Hum Pathol. 2006;37(4):381–390. doi: 10.1016/j.humpath.2006.01.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine. 2020;8(4):422. doi: 10.1016/S2213-2600(20)30076-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int [Internet] 2020;98(1):219–227. doi: 10.1016/j.kint.2020.04.003. Available from: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Lazaridis C, Vlachogiannis NI, Bakogiannis C, Spyridopoulos I, Stamatelopoulos K, Kanakakis I, et al. Involvement of cardiovascular system as the critical point in coronavirus disease 2019 (COVID-19) prognosis and recovery. Hellenic J Cardiol. 2019 doi: 10.1016/j.hjc.2020.05.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020 May 2–8;395(10234):1417–1418. doi: 10.1016/S0140-6736(20)30937-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020:2019–2021. doi: 10.1001/jama.2020.8259. [DOI] [PubMed] [Google Scholar]
  • 16.WHO, author. Infection prevention and control for the safe management of a dead body in the context of COVID-19: Interim guidance. WHO; 2020. Mar 24, p. 6. https://www.who.int/publications/i/item/infectionprevention-and-control-for-the-safe-management-of-a-dead-body-in-the-context-of-covid-19-interimguidance. [Google Scholar]
  • 17.Attoh SA, Hobenu F, Edusei L, et al. Postmortem diagnosis of COVID-19: Antemortem challenges of three cases at the 37 Military Hospital, Accra, Ghana. Afr J Lab Med. 2020;9(1):a1290. doi: 10.4102/ajlm.v9i1.1290. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Ghana Medical Journal are provided here courtesy of Ghana Medical Association

RESOURCES